New normal for the founding of biotech companies
In recent years, the number of newly founded biotech companies has been around a third of what it was at the turn of the millennium, but the Chairman of industry organization Dansk Biotek says he prefers to focus on framework conditions and funding rather than looking at the numbers.
BY STEFAN SINGH KAILAY
Scientific breakthroughs should have better conditions for being tested commercially, says the Chairman of industry organization Dansk Biotek, Martin Bonde, when MedWatch asks him about the number of new, Danish biotech companies that have received first-time funding in 2014.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
”There’s more money than there has been in years”
For abonnenter
Randi Krogsgaard leaves Dansk Biotek
For abonnenter
